Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ocular Myasthenia Gravis.

Victoria S. Pelak1, Steven L. Galetta

  • 1Departments of Neurology and Ophthalmology, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262, USA. victoria.pelak@UCHSC.edu; galetta@mail.med.upenn.edu

Current Treatment Options in Neurology
|June 8, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional Visual Loss.

Current treatment options in neurology·2003
Same author

Visual Hallucinations.

Current treatment options in neurology·2003
Same author

Orbital Inflammatory Disease.

Current treatment options in neurology·2002
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Ocular myasthenia gravis (OMG) treatment requires individualized drug therapy, often starting with anticholinesterase agents. While surgery is generally not recommended, thymectomy may benefit some patients, particularly those with thymoma.

Area of Science:

  • Neurology
  • Ophthalmology
  • Immunology

Background:

  • Ocular myasthenia gravis (OMG) presents with variable symptoms, necessitating tailored treatment strategies.
  • Non-pharmacologic interventions for ptosis and diplopia offer limited success, underscoring the need for drug therapy.

Purpose of the Study:

  • To outline evidence-based treatment decisions for ocular myasthenia gravis (OMG).
  • To review the efficacy and indications for various therapeutic modalities in OMG management.

Main Methods:

  • Review of current treatment guidelines and clinical observations for ocular myasthenia gravis.
  • Analysis of the role of anticholinesterase agents, corticosteroids, immunosuppressants, and surgical interventions.

Main Results:

Related Experiment Videos

  • Anticholinesterase agents are recommended as first-line or adjunctive therapy for OMG.
  • Corticosteroids are often essential for improving ophthalmoplegia and ptosis.
  • Thymectomy is advised for patients with thymoma and may benefit others without thymoma.

Conclusions:

  • Treatment decisions for OMG must be guided by symptomatology, with pharmacologic approaches being primary.
  • Surgical correction for ptosis or motility deficits is generally discouraged due to recurrence risks.
  • Screening for thymus tumors and considering thymectomy are crucial components of OMG management.